Physiological functions of VEGF in the retina and its possible implications prolonged anti-VEGF therapy

Vascular Endothelial Growth Factor (VEGF): Biology, Regulation and Clinical Significance

Volumn , Issue , 2013, Pages 117-136

  Klettner, Alexa ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891963860     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (103)

1. Yanoff, M; Sassani, JW. Ocular Pathology. 6th edition. Elsevier, 2009.
2. Robbins, SG; Conaway, JR; Ford, BL; Roberto, KA; Penn, JS. Detection of vascular endothelial growth factor (VEGF) protein in vascular and nonvascular cells of the normal and oxygeninjured rat retina. Growth Factors, 1997, 14, 229-41.
3. Famiglietti, EV; Stopa, EG; McGookin, ED; Song, P; LeBlanc, V; Streeten, BW. Immunocytochemical localization of vascular endothelial growth factor in neurons and glial cells of human retina. Brain Research, 2003, 969, 195-204.
4. Gerhardinger, C; Brown, LF; Roy, S; Mizutani, M; Zucker, CL; Lorenzi, M. Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy. American Journal of Pathology, 1998, 152, 1453-1462.
5. Hirata, C; Nakano, K; Nakamura, N; Kitagawa, Y; Shigeta, H; Hasegawa, G; Ogata, M; Ikeda, T; Sawa, T; Nakamura, K; Ienaga, K; Obayashi, H; Kondo, M. Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Müller cells. Biochemical and Biophysical Research Communications, 1997, 236, 712-715.
6. Stone, J; Itin, A; Alon, T; Pe'er, J; Gnessin, H; Chan-Ling, T; Keshet, E. Development of retina vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. Journal of Neuroscience, 1995, 15, 4738-4747.
7. Blaauwgeers, HGT; Holtkamp, GM; Rutten, H; Witmer, AN; Koolwijk, P; Partanen, TA; Alitalo, K; Kroon, ME; Kijlstra, A; van Hinsbergh, VWM; Schlingemann, RO. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris evidence for a trophic paracrine relation. American Journal of Pathology, 1999, 155, 421-428.
8. Saint-Geniez, M; Maldonado, AE; D'Amore, PA. VEGF expression and receptor activation in the choroid during development and in the adult. Investigative Ophthalmology & Visual Science, 2006, 47, 3135-3142.
9. Tischer, E; Mitchell, R; Hartman, T; Silva, M; Gospodarowicz, D; Fiddes, JC; Abraham, JA. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. Journal of Biological Chemistry, 1991, 266, 11947-11954.
10. Klettner, A; Roider, J. Treating age-related macular degeneration - interaction of VEGF antagonists with their target. Mini Reviews in Medicinal Chemistry, 2009, 9, 1127-1135.
11. Saint-Geniez, M; Kurihara, T; Sekiyama, E; Maldonado, A; D'Amore, P. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proceedings of the National Academy of Sciences USA, 2009, 106, 18751-18756.
12. Bergmann, M; Holz, F; Kopitz, J. Lysosomal stress and lipid peroxidation products induce VEGF-121 and VEGF-165 expression in Arpe19 cells. Graefe's Archive of Clinical and Experimental Ophthalmology, 2011, 249, 1477-1483.
13. Wang, H; Geisen, P; Wittchen, ES; King, B; Burridge, K; D'Amore, PA; Hartnett, ME. The role of RPE cell-associated VEGF189 in choroidal endothelial cell transmigration across the RPE. Investigative Ophthalmology & Visual Science, 2011, 52, 570-578.
14. Jingjing, L; Xue, Y; Agarwal, N; Roque, RS. Human Müller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor. Investigative Ophthalmology & Visual Science, 1999, 40, 752-759.
15. Bates, DO; Cui, TG; Doughty, JM; Winkler, M; Sugiono, M; Shields, JD; Peat, D; Gillatt, DA; Haper, SJ. VEGF165b, an inhibitory splice variant of VEGF, is down regulated in renal cell carcinoma. Cancer Research, 2002, 62, 4123-4131.
16. Hua, J; Spee, C; Kase, S; Rennel, ES; Magnussen, AL; Qui, Y; Varey, A; Dhayade, S; Churchill, AJ; Harper, SJ; Bates, DO; Hinton, DR. Recombinant human VEGF165b inhibits experimental choroidal neovascularization. Investigative Ophthalmology & Visual Science, 2010, 51, 4282-4288.
17. Konopatskaya, O; Churchill, AJ; Harper, SJ; Bates, DO; Gardinger, TA. VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularisation in mice. Molecular Vision, 2006, 12, 626-632.
18. Baba, T; McLeod, DS; Edwards, MM; Merges, C; Sen, T; Sinha, D; Lutty, GA. VEGF 165b in the developing vasculatures of the fetal human eye. Developmental Dynamics, 2012, 241, 595-607.
19. Nowak, DG; Woolard, J; Amin, EM; Konopatskaya, O; Saleem, MA; Churchill, AJ; Ladomery, MR; Harper, SJ; Bates, DO. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factor. Journal of Cell Science, 2008, 121, 3487-3495.
20. Varey, AHR; Rennel, ES; Qiu, Y; Bevan, HS; Perrin, RM; Raffy, S; Dixon, AR; Paraskeva, C; Zaccheo, O; Hassan, AB; Harper, SJ; Bates, DO. VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatments in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. British Journal of Cancer, 2008, 98, 1366-1379.
21. Woolard, J; Bevan, HS; Harper, SJ; Bates, OB. Molecular diversity of VEGF-A as a regulator of its biological activity. Microcirculation, 2009, 16, 572-592.
22. Kim, I; Ryan, AM; Rohan, R; Amano, S; Agular, S; Miller, JW; Adamis, AP. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Investigative Ophthalmology & Visual Science, 1999, 40, 2115-2121.
23. Saint-Geniez, M; Maharaj, ASR; Walshe, TE; Tucker, BA; Sekiyama, E; Kurihara, T; Darland, DC; Young, MJ; D'Amore, PA. Endogenous VEGF is required for visual function: Evidence for a survival role on Müller cells and photoreceptors. PloS One, 2008, 3, e3554.
24. Byeon, S; Lee, S; Choi, S; Lee, H; Lee, J; Chu, Y; Kwon, O. Vascular endothelial growth factor as an autocrine survival factor for retinal pigment epithelial cells under oxidative stress via the VEGF-R2/PI3K/Akt. Investigative Ophthalmology & Visual Science, 2010, 51, 1190-1197.
25. Nishiguchi, KM; Nakamura, M; Kaneko, H; Kachi, S: Terasaki, H. The role of VEGF and VEGFR2/Flk1 in proliferation of retinal progenitor cells in murine retinal degeneration. Investigative Ophthalmology & Visual Science, 2007, 48, 4315-4320.
26. Schwab, I. Evolution's witness: How eyes evolved. First edition. New York: Oxford University Press; 2012.
27. Chase, J. The evolution of retinal vascularization in mammals. Ophthalmology, 1982, 89, 1518-1525.
28. Provis, JM. Development of the primate retinal vasculature. Retinal and Eye Research, 2001, 20, 799-821.
29. Hughes, S; Yang, H; Chan-Ling, T. Vascularization of the human fetal retina: Roles of Vasculogenesis and Angiogenesis. Investigative Ophthalmology & Visual Science, 2000, 41, 1217-1228.
30. Stahl, A; Connor, KM; Sapieha, P; Chen, J; Dennison, RJ; Krah, NM; Seaward, MR; Willett, KL; Aderman, CM; Guerin, KI; Hua, J, Löfqvist, C; Hellström, A; Smith, LEH. The mouse retina as an angiogenesis model. Investigative Ophthalmology & Visual Science, 2010, 51, 2813-2826.
31. Provis, JM; Leech, J; Diaz, CM; Penfold, PL; Stone, J; Keshet, E: Development of the human retinal vasculature: Cellular relations and VEGF expression. Experimental Eye Research, 1997, 65, 555-568.
32. Gogat, K; Le Gat, L; Van Den Berghe, L; Marchant, D; Kobetz, A; Gadin, S; Gasser, B; Quéré, I; Abitbol, M; Menasche, M. VEGF and KDR gene expression during human embryonic and fetal eye development. Investigative Ophthalmology & Visual Science, 2004, 45, 7-14.
33. Robinson, GS; Ju, M; Shih, S-C; Xu, X; McMahon, G; Caldwell, RB; Smith, LEH. Nonvascular role for vascular endothelial growth factor (VEGF): VEGFR-1 and VEGFR-2 activity is critical for neural retinal development. FASEB Journal, 2001, 15, 1215-1217.
34. Fruttiger, M. Development of the mouse retinal vasculature: Angiogenesis versus vasculogenesis. Investigative Ophthalmology & Visual Science, 2002, 43, 522-527.
35. Curatola, AM; Moscatelli, D; Norris, A; Hendricks-Munoz, K. Retinal blood vessels develop in response to local VEGF-A signals in the absence of blood flow. Experimental Eye Research, 2005, 81, 147-158.
36. Stalmans, I; Ng, Y-S; Rohan, R; Fruttiger, M; Bouché, A; Ÿuce, A; Fujisawa, H; Hermans, B; Shani, M; Jansen, S; Hicklin, D; Anderson, DJ; Gardiner, T; Hammes, H-P; Moons, L; Dewerchin, M; Collen, D; Carmeliet, P; D'Amore, PA. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. Journal of Clinical Investigation, 2002, 109, 327-336.
37. Gerhardt, H; Golding, M; Fruttiger, M; Ruhrberg, C; Lundkvist, A; Abramsson, A; Jeltsch, M; Mitchell, C; Alitalo, K; Shima, D; Betsholtz, C. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. Journal of Cell Biology, 2003, 161, 1163-1177.
38. Ishida, U; Usui, T; Yamashiro, K; Kaji, Y; Amano, S; Ogura, Y; Hida, T; Oguchi, Y; Ambati, J; Miller, JW; Gragoudas, ES; Ng, YS; D'Amore, PA; Shima, DT; Adamis, AP. VEGF164-mediated inflammation is required for pathological, but not physiological ischemia-induced retinal neovascularization. Journal of Experimental Medicine, 2003, 198, 483-489.
39. Alon, T; Hemo, I; Itin, A; Pe'er, J; Stone, J; Keshet, E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Medicine, 1995, 1(10), 1024-8.
40. Scott, A; Powner, MB; Gandhi, P; Clarkin, C; Gutmann, DH; Johnson, RS; Ferrara, N; Fruttiger, M. Astrocyte-derived vascular endothelial growth factor stabilizes vessels in the developing retinal vasculature. PloS One, 2010, 5, e11863.
41. Uemura, A; Kusuhara, S; Katsuta, H; Nishikawa, S-I. Angiogenesis in the mouse retina: A model system for experimental manipulation. Experimental Cell Research, 2006, 312, 676-683.
42. Weidemann, A; Krohne, TU; Aguilar, E; Kurihara, T; Takeda, N; Dorrell, MI; Simon, MC; Haase, VH; Friedlander, M: Johnson, RS. Astrocyte hypoxic response is essential for pathological but not developmental angiogenesis of the retina. Glia, 2010, 58, 1177-1185.
43. Bai, Y; Ma, JX; Guo, J; Wang, J; Zhu, M; Chen, Y; Le, YZ. Müller cell-derived VEGF is a significant contributor to retinal neovascularization. Journal of Pathology, 2009, 219, 446-454.
44. Yi X, Mai LC, Uyama M, Yew DT. Time-course expression of vascular endothelial growth factor as related to the development of the retinochoroidal vasculature in rats. Experimental Brain Research, 1998, 118, 155-160.
45. Sapieha, P. Eyeing central neurons in vascular growth and reparative angiogenesis. Blood, 2012, 120, 2182-2194.
46. Chan-Ling, T; Dahlstrom, JE; Koina, ME; McColm, JR; Sterling, R-A; Bean, EG; Adamson, S; Hughes, S; Baxter, LC. Evidence of hematopoietic differentiation, vasculogenesis and angiogenesis in the formation of human choroidal blood vessels. Experimental Eye Research, 2011, 92, 361-376.
47. Lutty, GA; Hasegawa, T; Baba, T; Grebe, R; Bhutto, I; McLeod, DS. Development of the human choriocapillaris. Eye, 2010, 24, 408-415.
48. Zhao, S; Overbeek, PA. Regulation of choroid development by the retinal pigment epithelium. Molecular Vision, 2001; 7, 277-282.
49. Zhao, J; Song, Y; Wang, Y; Zhang, X. Regulation effect of vascular endothelial growth factor on human fetal choroid vascularization. Yan Ke Xue Bao, 2000, 16, 11-14.
50. Marneros, AG; Fan, J; Yokoyama, Y; Gerber, HP; Ferrara, N; Crouch, RK; Olsen, BR. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol, 2005, 167, 1451-1459.
51. Le, YZ; Bai, Y; Zhu, M; Zheng, L. Temporal requirement of RPE-derived VEGF in the development of choroidal vasculature. J Neurochem, 2010, 112, 1584-1592.
52. Sandercoe, TM; Geller, SF; Hendrickson, AE; Stone, J; Provis, JM. VEGF expression by ganglion cells in central retina before formation of the foveal depression in monkey retina: evidence of developmental hypoxia. Journal of Comparative Neurology, 2003, 462, 42-54.
53. Young, RW. The ninth Frederick H. Verhoeff Lecture, the life history of retinal cells. Transactions of the American Ophthalmological Society, 1983, 81, 193-228.
54. Yang, X; Cepko, CL. Flk-1, a Receptor for vascular endothelial growth factor (VEGF), is expressed by retinal progenitor cells. Journal of Neuroscience, 1996, 16, 6089-6099.
55. Hinds, JW; Hinds, PL. Early ganglion cell differentiation in the mouse retina: An electron microscopic analysis utilizing serial sections. Developmental Biology, 1974, 37, 381-416.
56. Hashimoto, T; Zhang, XM; Chen, BYK; Yang, XJ. VEGF activates divergent intracellular signaling components to regulate retinal progenitor cell proliferation and neuronal differentiation. Development, 2006, 133, 2201-2210.
57. Kur, J; Newman, EA; Chan-Ling, T. Cellular and physiological mechanisms underlying blood flow regulation in the retina and choroid in health and disease. Progress in Retinal and Eye Research, 2012, 31, 377-406.
58. Buttery, RG; Hinrichsen, CFL; Weller, WL; Haight, JR. How thick should a retina be? A comparative study of mammalian species with and without intraretinal vasculature. Vision Research, 1991, 31, 169-187.
59. Nickla, D; Wallman, J. The multifunctional choroid. Progress in Retinal and Eye Research, 2010, 29, 144-168.
60. Eremina, V; Sood, S; Haigh, J; Nagy, A; Lajoie, G; Ferrara, N; Gerber, H-P; Kikkawa, Y; Miner, JH; Quaggin, SE. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. Journal of Clinical Investigation, 2003, 111, 707-716.
61. Jia, Q; McDill, BW; Sankarapandian, B; Wu, S; Liapis, H; Holzman, LB; Capecchi, MR; Miner, JH; Chen, F. Ablation of developing podocytes disrupts cellular interactions and nephrogenesis both inside and outside the glomerulus. American Journal of Physiology - Renal Physiology, 2008, 295, F1790-F1798.
62. Maharaj, ASR; Saint-Geniez, M; Maldonado, AE; D'Amore, PA. Vascular endothelial growth factor localization in the adult. American Journal of Pathology, 2006, 168, 639-648.
63. Korte, GE; Reppucci, V; Henkind, P. RPE destruction causes choriocapillary atrophy. Investigative Ophthalmology & Visual Science, 1984, 25, 1135-1145.
64. McLeod, DS; Grebe, R; Bhutto, I; Merges, C; Baba, T; Lutty, GA. Relationship between RPE and choriocapillaris in age-related macular degeneration. Investigative Ophthalmology & Visual Science, 2009, 50, 4982-4991.
65. Maminishkis, A; Chen, S; Jalickee, S; Banzon, T; Shi, G; Wang, FE; Ehalt, T; Hammer, JA; Miller, SS. Confluent monolayers of cultured human fetal retinal pigment epithelium exhibit morphology and physiology of native tissue. Investigative Ophthalmology & Visual Science, 2006, 47, 3612-3624.
66. Peters, S; Heiduschka, P; Julien, S; Ziemssen, F; Fietz, H; Bartz-Schmidt, KU; The Tübingen Bevacizumab Study Group, Schraermeyer, U. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. American Journal of Ophthalmology, 2007, 143, 995-1002.
67. Shimomura, Y; Hirata, A; Ishikawa, S; Okinami, S. Changes in choriocapillaris fenestration of rat eyes after intravitreal bevacizumab injection. Graefe's Archive of Clinical and Experimental Ophthalmology, 2009, 247, 1089-1094.
68. Kurihara, T; Westenskow, PD; Bravo, S; Aguilar, E; Friedlander, M. Targeted deletion of Vegfa in adult mice induces vision loss. The Journal of Clinical Investigation, 2012, 122, 4213-4217.
69. Ueno, S; Pease, ME; Bonnet Wersinger, DM; Masuda, T; Vinores, SA; Licht, T; Zack, DJ; Quigley, H; Keshet, E; Campochiaro, PA. Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels. Journal of Cellular Physiology, 2008, 217, 13-22.
70. Ford, KM; Saint-Geniez, M; Walshe, T; Zahr, A; D'Amore, PA. Expression and role of VEGF in the adult retinal pigment epithelium. Investigative Ophthalmology & Visual Science, 2011, 52, 9478-9487.
71. Gerber, HP; McMurtrey, A; Kowalski, J; Yan, M; Keyt, BA; Dixit, V; Ferrara, N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'kinase/Akt signal transduction pathway. Journal of Biological Chemistry, 1998, 273, 30336-30343.
72. El-Remessy, AB; Bartoli, M; Platt, DH; Fulton, D; Caldwell, RB. Oxidative stress inactivates VEGF survival signalling in retinal endothelial cells via PI3-kinase tyrosine nitration. Journal of Cell Science, 2005, 118, 243-252.
73. Magnussen, AL; Rennel, ES; Hua, J; Bevan, HS; Long, NB; Lehrling, C; Gammons, M; Floege, J; Harper, SJ; Agostini, HT; Bates, DO, Churchill, AJ. VEGF-A165b Is cytoprotective and antiangiogenic in the retina. Investigative Ophthalmology & Visual Science, 2010, 51, 4273-4281.
74. Kilic, Ü; Kilic, E; Järve, A; Guo, Z; Spudich, A; Bieber, K; Barzena, U; Bassetti, CL; Marti, HH; Hermann, DM. Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating Erk1/2 and Akt pathways. Journal of Neuroscience, 2006, 26, 12439-12446.
75. Geisen, P; McColm, JR; Hartnett, ME. Choroidal endothelial cells transmigrate across the retinal pigment epithelium but do not proliferate in response to soluble vascular endothelial growth factor. Experimental Eye Research, 2006, 82, 608-619.
76. Zachary, I. Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function and therapeutic potential. Neurosignals, 2005, 14, 207-221.
77. D'Amore, PA: Vascular Endothelial Cell Growth Factor-A. Not just for endothelial cells anymore. American Journal of Pathology, 2007, Vol. 171, 14-18.
78. Böcker-Meffert, S; Rosenstiel, P; Röhl, C; Warneke, N; Held-Feindt, J; Sievers, J; Lucius, R. Erythropoietin and VEGF promote neural outgrowth from retinal explants in postnatal rats. Investigative Ophthalmology & Visual Science, 2002, 43, 2021-2026.
79. Nishijima, K; Ng, YS; Zhong, L; Bradley, J; Schubert, W; Jo, N; Akita, J; Samuelsson, SJ; Robinson, GS; Adamis, AP; Shima, DT. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. American Journal of Pathology, 2007, 171, 53-67.
80. Brar, VS; Sharma, RK; Murthy, RK; Chalam, KV. Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal gangion cells. Molecular Vision, 2010, 16, 1848-1853.
81. Suzuki, M; Ozawa, Y; Kubota, S; Hirasawa, M; Miyake, S; Noda, K; Tsubota, K; Kadonosono, K; Ishida, S. Neuroprotective response after photodynamic therapy: Role of vascular endothelial growth factor. Journal of Neuroinflammation, 2011, 8, 176-177.
82. Wang, H; Geisen, P; Wittchen, E; King, B; Burridge, K; D'Amore, P; Hartnett, M. The role of RPE cell-associated VEGF189 in choroidal endothelial cell transmigration in neovascular age-related macular degeneration. Investigative Ophthalmology & Visual Science epub, 2010, 59, 2297-2305.
83. Miki, A; Miki, K; Ueno, S; Wersinger, DMB; Berlinicke, C; Shaw, GC; Usui, S; Wang, Y; Zack, DJ; Campochiaro, PA. Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells. Journal of Cellular Physiology, 2010, 224, 262-272.
84. Strauss O. The retinal pigment epithelium in visual function. Physiological Reviews, 2005, 85, 845-881.
85. Kehler, AK; Andersen, C; Andreasen, JR; Vohra, R; Junker, N; Poulsen, KA; Kolko, M. Interaction between VEGF and calcium-independent phospholipase A2 in proliferation and migration of retinal pigment epithelium. Current Eye Research, 2012, 37, 500-507.
86. Klettner, A; Möhle, F; Roider, J. Intracellular bevacizumab reduces phagocytotic uptake in RPE cells. Graefe's Archive of Clinical and Experimental Ophthalmology, 2010, 248, 819-824.
87. Klettner, A; Westhues, D; Lassen, J; Bartsch, S; Roider, J. Regulation of constitutive vascular endothelial growth factor secretion in retinal pigment epithelium/choroid organ cultures: p38, nuclear factor kappaB, and the vascular endothelial growth factor receptor-2/phosphatidylinositol 3 kinase pathway. Molecular Vision, 2013, 19, 281-291.
88. Klettner, A. Oxidative stress induced cellular signaling in RPE cells. Frontiers in Bioscience, 2012, 4, 392-411.
89. Kannan, R; Zhang, N; Sreekumar, P; Spee, C; Rodriguez, A; Barron, E; Hinton, D. Stimulation of apical and basolateral vascular endothelial growth factor-A and vascular endothelial growth factor-C secretion by oxidative stress in polarized retinal pigment epithelial cells. Molecular Vision, 2006, 12, 1649-1659.
90. Klettner, A; Roider, J. Constitutive and oxidative-stress-induced expression of VEGF in the RPE are differently regulated by different Mitogen-activated protein kinases. Graefe's Archive of Clinical and Experimental Ophthalmology, 2009, 247, 1487-1492.
91. Senger, DR; Galli, SJ; Dvorak, AM; Perruzzi, CA; Harvey, VS; Dvorak, HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 1983, 219, 983-985.
92. Connolly, DT. Vascular permeability factor: A unique regulator of blood vessel function. Journal of Cellular Biochemistry, 1991, 47, 219-223.
93. Miura, Y; Klettner, A; Roider, J. VEGF antagonists decrease barrier function of retinal pigment epithelium in vitro: Possible participation of intracellular glutathione. Investigative Ophthalmology & Visual Science, 2010, Vol. 51, 4848-4855.
94. Peng, S; Adelman, RA; Rizzolo, LJ. Minimal effects of VEGF and Anti-VEGF drugs on the permeability or selectivity of RPE tight junctions. Investigative Ophthalmology & Visual Science, 2010, 51, 3216-3225.
95. Sato, T; Wada, K; Arahori, H; Kuno, N; Imoto, K; Iwahashi-Shima, C; Kusaka, S. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. American Journal of Ophthalmology, 2012, 153, 327-333.
96. Hård, A-L. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment - a review. Acta Pædiatrica, 2011, 100, 1523-1527.
97. Lutty, GA; McLeod, DS; Bhutto, I; Wiegand, SJ. Effect of VEGF trap on normal retinal vasculature development and oxygen-induced retinopathy in the dog. Investigative Ophthalmology & Visual Science, 2011, 52, 4039-4047.
98. Miller, JW; Le Couter, J; Strauss, EC; Ferrara, N. Vascular endothelial growth factor A in intraocular vascular disease. Ophthalmology, 2013, 120, 106-114.
99. Spitzer, MS; Yoeruek, K; Sierra, A; Wallenfels-Thilo, B; Schraermeyer, U; Spitzer, B; Bartz-Schmidt, KU; Szurman, P. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefe's Archive of Clinical and Experimental Ophthalmology, 2007, 245, 1837-1842.
100. Sakurai, K; Akiyama, H; Shimoda, Y; Yoshida, I; Kurabayashi, M; Kishi, S: Effect of intravitreal injection of high-dose bevacizumab in monkey eyes. Investigative Ophthalmology & Visual Science, 2009, 50, 4905-4916.
101. Inan,ÜÜ; Avci, B; Kusbeci, T; Kaderli, B; Avci, R; Temel, SG. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Investigative Ophthalmology & Visual Science, 2007, 48, 1773-1781.
102. Rosenberg, PJ; Shapiro, H; Tuomi, L; Webster, M; Elledge, J; Blodi, B; MARINA and ANCHOR Study Groups. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology, 2011, 118, 523-530.
103. Uemoto, R; Nakasato-Sonn, H; Kawagoe, T; Akira, M; Okada, E; Mizuki, N. Factors associated with enlargement of chorioretinal atrophy after intravitreal bevacizumab for myopic choroidal neovascularization. Graefe's Archive of Clinical and Experimental Ophthalmology, 2012, 250, 989-997.